Reduce the chaos of RSV season with BeyfortusTM (nirsevimab-alip) - protection for any infant

Power to help prevent respiratory syncytial virus (RSV) disease

Order Beyfortus Packaging Image

Start Planning for the 2024/2025 Season Today

ACIP AND AAP RECOMMENDED¹⁻³*

View press release

Beyfortusᵀᴹ (nirsevimab-alip) is the first and only long-acting antibody indicated for the prevention of RSV lower respiratory tract disease in⁴:

Neonates and infants icon
Neonates and infants born during or entering their first RSV season
Children up to 24 months of age icon
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
Safety icon

Demonstrated safety and
efficacy profile⁴


Syringe icon

Pre-filled syringe for
convenient administration⁴


Woman with infant image

Keep Up to Date With Information About Beyfortus via Email or Text

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.